Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Neuro-Oncology Practice|July 15, 2024
Baseline total brain volume predicts changes in quality of life and overall survival after cranial radiotherapy in older patients with glioblastoma: Results from the prospective BRITER studyCressida Lorimer, Samantha Mills, Anthony Chalmers, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2015
Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II TrialNicholas MacLeod, Anthony Chalmers, Noelle O'Rourke, et al.Radiation Oncology (London, England)|April 17, 2012
Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reducedTurid Hellevik, Ingvild Pettersen, Vivian Berg, et al.BMJ Open|November 26, 2016
Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational studySelina Tsim, Caroline Kelly, Laura Alexander, et al.Neuro-Oncology Advances|June 19, 2023
Glioblastoma extracellular vesicles influence glial cell hyaluronic acid deposition to promote invasivenessDominik Koessinger, David Novo, Anna Koessinger, et al.Neuro-Oncology Practice|July 15, 2024
Inequalities in access to neuro-oncology supportive care and rehabilitation: A survey of healthcare professionals' perspectivesFlorien Boele, Lena Rosenlund, Sara Nordentoft, et al.BMC Cancer|May 7, 2020
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trialRobert Olson, Lindsay Mathews, Mitchell Liu, et al.International Journal of Radiation Oncology, Biology, Physics|July 30, 2026
Project Optimus for Radiation Therapy-Drug Combinations: Moving Beyond the Maximum Tolerated DoseAlastair Greystoke, Sarah Brown, Anthony Chalmers, et al.BMC Cancer|August 21, 2019
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trialDavid A Palma, Robert Olson, Stephen Harrow, et al.Nature|September 20, 2019
Glutamatergic synaptic input to glioma cells drives brain tumour progressionVarun Venkataramani, Dimitar Ivanov Tanev, Christopher Strahle, et al.Pageof 3